Novel drug therapies for atrial fibrillation
Atrial fibrillation is the most common sustained arrhythmia and imposes a substantial burden on patients and health-care providers. Clinical evidence suggests that antiarrhythmic therapy to restore and maintain sinus rhythm (rhythm control) can reduce adverse cardiovascular outcomes in patients with...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | Article (Journal) |
| Lenguaje: | inglés |
| Publicado: |
May 2024
|
| In: |
Nature reviews. Cardiology
Year: 2024, Volumen: 21, Número: 5, Pages: 275-276 |
| ISSN: | 1759-5010 |
| DOI: | 10.1038/s41569-024-01004-2 |
| Acceso en línea: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/s41569-024-01004-2 Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/s41569-024-01004-2 
|
| Notas de Autor: | Felix Wiedmann, Constanze Schmidt |
| Sumario: | Atrial fibrillation is the most common sustained arrhythmia and imposes a substantial burden on patients and health-care providers. Clinical evidence suggests that antiarrhythmic therapy to restore and maintain sinus rhythm (rhythm control) can reduce adverse cardiovascular outcomes in patients with new-onset atrial fibrillation. As a result, a paradigm shift towards rhythm control over rate control therapy is emerging, increasing the clinical need for effective and safe antiarrhythmic drugs. |
|---|---|
| Notas: | Online veröffentlicht: 28. Februar 2024 Gesehen am 28.11.2024 |
| Descripción Física: | Online Resource |
| ISSN: | 1759-5010 |
| DOI: | 10.1038/s41569-024-01004-2 |